Linear pharmacokinetic behavior of ropinirole during multiple dosing in patients with Parkinson's disease

Academic Article


  • The objectives of this study were to measure the pharmacokinetics of ropinirole at steady state when the drug is used as an adjunct to L-dopa and evaluate the long-term tolerability of ropinirole in this indication. Twenty-four patients who were taking L-dopa for Parkinson's disease and experiencing a lack of symptomatic control were recruited. Patients received open-label adjunctive treatment with ropinirole for up to 2 years. The starting dose was 0.5 mg bid, which could be titrated to a maximum of 6.0 mg tid. Ropinirole demonstrated approximately dose-linear pharmacokinetics at steady state; corresponding values were higher during tid than bid dosing. A reduction in mean L-dopa dose was maintained throughout the trial. The combination of L-dopa and ropinirole was generally well tolerated, with only I patient withdrawing from treatment because of adverse events. Thus, ropinirole shows approximately linear steady-state pharmacokinetics and a good safety profile when administered with L-dopa. (C) 2000 American College of Clinical Pharmacology.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Hubble J; Koller WC; Atchison P; Taylor AC; Citerone DR; Zussman BD; Friedman CJ; Hawker N
  • Start Page

  • 641
  • End Page

  • 646
  • Volume

  • 40
  • Issue

  • 6